A

nd so, another working week will soon draw to a close. Not a moment too soon, yes? This is, you may recall, our treasured signal to daydream about weekend plans. And our agenda is rather modest. We need to tidy up around the castle, catch up on our napping, and plan to spend time with our short person. We may also promenade with the mascots. And what about you? Perhaps this is a good time to plan a spring break, reach out to someone special, or donate to the arts, which may need some help. Or you could check to see if you were wiretapped recently. But please do remember to gather evidence. Well, whatever you do, have a grand time, but be safe. Enjoy, and see you soon …

AstraZeneca was dealt another setback by the Food and Drug Administration in its quest to win approval for a drug that treats hyperkalemia, a condition in which potassium levels in the blood are too high, the Financial Times says. The FDA issued a complete response letter, meaning the drug will not be approved. This is the second time the FDA declined to approve the drug, which AstraZeneca acquired when it bought ZS Pharma for $2.7 billion in 2015.

This is a STAT Plus article and you can unlock it by subscribing to STAT Plus today. It's easy! Your first 30 days are free and if you don't enjoy your subscription you can cancel any time.
Already a subscriber? Log in here.

Leave a Comment

Please enter your name.
Please enter a comment.

Sign up for our Morning Rounds newsletter

Your daily dose of news in health and medicine.

X